Experience with pre-diluted plasma exchange therapy for hyperviscosity syndrome.
hyperviscosity syndrome
intracircuit coagulation
plasma exchange
pre-dilution
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
06
01
2023
accepted:
09
02
2023
medline:
6
11
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
ppublish
Résumé
Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method. Physiological saline is injected in front of the plasma separation membrane to pre-dilute the blood, followed by filtration through the plasma separation membrane. As a result of pre-diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount. In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment.
Identifiants
pubmed: 37605348
doi: 10.1111/1744-9987.14053
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035-1039Informations de copyright
© 2023 International Society for Apheresis and Japanese Society for Apheresis.
Références
Rogers AP, Estes M. Hyperviscosity syndrome. StatPearls Publishing; 2023.
Schatz MJ, Wilkins CS, Otero-Marquez O, Chui TYP, Rosen RB, Gupta M. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis. Case Rep Ophthalmol Med. 2021;5:6816195.
Yoshihisa M. Primary macroglobulinemia (WM) and multiple myeloma and plasmapheresis [genpatsuseimacroglobulinekesyou oyobi tahatsuseikotsuzuisyu to kesyoukoukan]. Hematol Front. 2018;28(10):1487-1495.
Hamasaki Y. Apheresis in hematologic diseases focusing on plasmapheresis [ketsuekishikanniokeru apheresiskesyoukoukanwo chushinni]. Hematol Front. 2018;28(10):1435-1440.
Osada A, Goto K, Urahama Y, Ooishi H, Ueda N, Watamoto K, et al. Two case of plasmapheresis to Waldenstrom's macroglobulinemia with hyperviscosity syndrome. Jpn J Apher. 2017;Supplement 36:125.
Araki K, Kurata K, Inaba S, Kudo N, Kato H, Sezaki T, et al. Experience of blood dilution of DFPP circuit to prevent plasmapheresis membranes from obstruction. Jpn J Apher. 2017;Supplement 36:125.
Takezako N. Hyperviscosity syndrome. Intern Med. 2017;120(4):941-944.
Hirayama C, Kamizato K. Technology of apheresis therapy, plasma exchange [apheresis ryouhounogijutsu, tanjunkesyoukoukanhou]. Jpn J Apher. 2021;40(3):464-472.
Ohkubo A. Basics of apheresis therapy, replacement solution in apheresis [apheresisryouohunokiso, apheresisniokeruchikaneki]. Jpn J Apher. 2021;40(3):423-431.
Ohkubo A, Sakurasawa T, Hoshi M. Comparison of membrane separation and centrifugation for therapeutic plasma exchange. Jpn J Apher. 2022;41(2):137-141.
Ueda Y. Real world practice, guidelines and public insurance coverage of japanese hemapheresus for hematolobical issues. Jpn J Apher. 2022;41(3):164-169.